Research programme: bone cell regulators - Bone MedicalAlternative Names: BN 005; BN 008
Latest Information Update: 01 Feb 2013
At a glance
- Originator Bone Medical
- Developer Bone Medical; University of Queenslands Institute for Molecular Bioscience
- Class Peptides
- Mechanism of Action Osteoblast stimulants; Osteoclast inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Osteoporosis
Most Recent Events
- 28 Jan 2013 Early research is ongoing in Australia
- 13 Aug 2007 Early research in Osteoporosis in Australia (unspecified route)